临床外科杂志 ›› 2023, Vol. 31 ›› Issue (12): 1180-1183.doi: 10.3969/j.issn.1005-6483.2023.12.020

• 论著 • 上一篇    下一篇

BRAFV600E在甲状腺良恶性及交界性病变检测中的价值

  

  1. 010000 呼和浩特,内蒙古医科大学基础医学院
  • 收稿日期:2022-12-02 出版日期:2023-12-20 发布日期:2023-01-15
  • 通讯作者: 孙勤暖,Email:sunqinnuan@163.com
  • 基金资助:
    内蒙古自治区科学基金项目(编号:2017MS08125)

Significance of BRAFV600E protein and gene detection in benign,malignant and borderline thyroid diseases

  1. School of Basic Medicine,Inner Mongolia Medical University,Hohhot,Inner Mongolia 010000,China
  • Received:2022-12-02 Online:2023-12-20 Published:2023-01-15

摘要: 目的 探讨BRAFV600E在甲状腺良恶性及交界性病变检测中的价值。方法 选取我院2010年1月2018年12月收治的手术切除甲状腺乳头状癌(papillary thyroid carcinoma,PTC)病理标本273例,其中经典亚型(classical variant of papillary carcinoma,CVPTC)254例,滤泡亚型(follicular variant of papillary carcinoma,FVPTC)19例,良性病变30例,选取HE诊断不确定的交界性病变17例,分别进行BRAFV600E蛋白免疫组化染色,其中再选取CVPTC 17例、FVPTC 12例、交界性病变17例、良性病变13例进行BRAFV600E聚合酶链反应(polymerase chain reaction,PCR)检测,观察BRAFV600E基因突变与蛋白表达情况及相互关系。结果 BRAFV600E蛋白在CVPTC、FVPTC、交界性病变、良性病变组织中表达阳性率分别为86.6%、15.9%、23.5%、26.7%,BRAFV600E基因在CVPTC、FVPTC、交界性病变、良性病变组织中突变率分别为82.4%、41.7%、23.5%、0,BRAFV600E蛋白在CVPTC与FVPTC、交界性病变、良性病变表达比较,差异有统计学意义(P<0.05);BRAFV600E基因突变在CVPTC与FVPTC、交界性病变比较,差异有统计学意义(P<0.05);BRAFV600E基因突变与蛋白表达在CVPTC中的吻合系数K=0.821,P<0.05。在CVPTC中 BRAFV600E蛋白阳性表达与性别、年龄、肿瘤直径、淋巴结是否转移无关(P>0.05),与组织学分型、被膜侵犯相关(P<0.05)。结论 BRAFV600E对甲状腺良恶性及交界性病变诊断及鉴别诊断有参考价值。

关键词: BRAFV600E, 甲状腺乳头状癌, 交界性病变, 免疫组织化学

Abstract: Objective To investigate the significance of BRAFV600E in the detection of benign,malignant and borderline thyroid lesions. Methods A total of 273 formalin fixed and paraffinembedded specimens of papillary thyroid carcinoma (PTC) were selected for study from January 2010 to December 2018 .There were 254 cases of classical variant of papillary carcinoma (CVPTC) and 19 cases of follicular variant of papillary carcinoma (FVPTC).30 benign lesions were made into tissue microarray (TMA),and 17 uncertain borderline lesions diagnosed by HE.Polymerase chain reaction (PCR) was used to detect 17 cases of CVPTC 12 cases of FVPTC 17 cases of borderline lesions and 13 cases of benign lesions. BRAFV600E gene mutation and protein expression were observed. Results The positive expression rates of BRAFV600E protein in CVPTC,FVPTC,borderline lesion and benign lesion were 86.6%,15.9%,23.5% and 26.7%,respectively.Mutation rates of BRAFV600E gene in CVPTC,FVPTC,borderline lesions and benign lesions were 82.4%,41.7%,23.5% and 0,respectively.There were significant differences in expression of BRAFV600E protein in CVPTC,FVPTC,borderline lesions and benign lesions(P<0.05).There was statistically significant difference between BRAFV600E gene mutation in CVPTC and FVPTC and borderline diseases(P<0.05).The coincidence coefficient between BRAFV600E gene mutation and protein expression in CVPTC was K=0.821,P<0.05.It was statistically significant.The positive expression of BRAFV600E protein in PTC was not correlated with gender,age,tumor size and lymph node metastasis (P>0.05),but was correlated with tissue type and capsule invasion (P<0.05). Conclusion BRAFV600E has reference value in the diagnosis and differential diagnosis of benign and malignant thyroid and borderline thyroid lesions.

Key words: BRAFV600E, papillary thyroid carcinoma, borderline lesion, immunohistochemistry

[1] 费建平 刘宏伟. 甲状腺乳头状癌喉返神经深层面淋巴结转移的影响因素分析[J]. 临床外科杂志, 2023, 31(1): 57-59.
[2] 谢天皓 刘洋 刘雅涵 刘小爽 王同 孙谦 张景 刘立涛 孙新利 任项项 靳小石. 腔镜甲状腺癌手术中应用纳米碳对甲状旁腺功能保护的应用分析[J]. 临床外科杂志, 2022, 30(9): 865-868.
[3] 达娃卓玛 王雨晨 刘士强 夏耘. 结节性硬化症合并甲状腺乳头状癌一例[J]. 临床外科杂志, 2022, 30(4): 391-392.
[4] 李铃睿 宋俊龙 刘汉卿 孔德光 陈创. 甲状腺乳头状癌的基因变异与临床病理特点分析[J]. 临床外科杂志, 2022, 30(3): 222-225.
[5] 顾青青 王建华 陈国芳 曹晨燕. 多发性内分泌腺瘤病1型二例[J]. 临床外科杂志, 2022, 30(3): 226-229.
[6] 蒋树云 马德寿 王宁 许召君 刘韬 马志军. 家族性甲状腺乳头状癌二例[J]. 临床外科杂志, 2022, 30(10): 933-934.
[7] 何领 徐鲲 任明 陈晨 郭嵩 朱太阳 陈德轩 高国宇 王高元. 伴桥本甲状腺炎的甲状腺乳头状癌临床病理特征及其手术策略[J]. 临床外科杂志, 2022, 30(1): 40-43.
[8] 穆静辉, 冯文静. 甲状腺乳头状癌伴发桥本甲状腺炎行甲状腺全切手术后生存质量分析[J]. 临床外科杂志, 2021, 29(8): 761-763.
[9] 周雷 丁胜义 王朝 陈磊. 甲状腺乳头状癌病人甲状腺全切术右侧喉返神经深层淋巴结转移情况分析[J]. 临床外科杂志, 2021, 29(7): 652-655.
[10] 郑媛 陈波. 浸润性导管癌合并导管原位癌的临床病理特点分析[J]. 临床外科杂志, 2021, 29(11): 1047-1049.
[11] 马静 张楠 马斌林. 甲状腺乳头状癌病人血清微小RNA-451的检测及其诊断价值的研究[J]. 临床外科杂志, 2021, 29(10): 953-956.
[12] 杨晓华 吴淑华. 磷脂酰肌醇3-激酶p110α/β在甲状腺乳头状癌组织中的表达及与预后的相关性[J]. 临床外科杂志, 2021, 29(1): 74-77.
[13] 何领 徐鲲 任明 陈德轩 高国宇 孟娣娟. 甲状腺乳头状癌术后甲状旁腺功能减退的预测因素分析〖[J]. 临床外科杂志, 2020, 28(9): 853-856.
[14] 林安忆 潘华锋 李琰. 血清特异miRNAs的检测在甲状腺乳头状癌诊断中的意义分析[J]. 临床外科杂志, 2020, 28(3): 231-234.
[15] 杨炳石 闫桂玲 黄燕 江志静. 甲状腺系膜切除术对甲状腺癌病人生存率影响[J]. 临床外科杂志, 2020, 28(3): 236-239.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!